White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens
about
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaDifficulties in demonstrating superiority of an antibiotic for multidrug-resistant bacteria in nonrandomized studiesRegulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the GoodShould we treat patients with only one set of positive blood cultures for extensively drug-resistant Acinetobacter baumannii the same as multiple sets?EUropean prospective cohort study on Enterobacteriaceae showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observational study.New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.The future of antibioticsThe evolution of the regulatory framework for antibacterial agentsNovel approaches are needed to develop tomorrow's antibacterial therapiesFosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals.The future of antibiotics and resistance.Noninferior Antibiotics: When Is "Not Bad" "Good Enough"?The FDA reboot of antibiotic development.Exploiting Interkingdom Interactions for Development of Small-Molecule Inhibitors of Candida albicans Biofilm Formation.Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistancePIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies.Prioritized current unmet needs for antibacterial therapies.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice.Antibiotics Clinical Development and Pipeline.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.The time-dependent "cure-death" model investigating two equally important endpoints simultaneously in trials treating high-risk patients with resistant pathogens.Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.The value of single-pathogen antibacterial agents.Methods for efficacy evaluations of antibacterial treatments in multiple body-site infection trials.Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.Is the GAIN Act a turning point in new antibiotic discovery?Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat".Hierarchical nested trial design (HNTD) for demonstrating treatment efficacy of new antibacterial drugs in patient populations with emerging bacterial resistance.Consistency ensured test strategies for supportive evidence of treatment efficacy in noninferiority clinical trials.Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function.Distribution of virulence-associated genes and antimicrobial susceptibility in clinical Acinetobacter baumannii isolates.
P2860
Q24601746-4A62943F-99D1-43FE-9FE8-8F114DEEAAC2Q26863059-8C1C6545-7A4C-43F8-8335-717EA44C72C7Q28468531-B19C9835-5BE3-491B-AE90-B7EC9FC733F7Q33443422-9F71D71C-7432-4AC0-9547-25EA151CCCD3Q33552772-0C273EBB-0B1B-4AA8-9240-1CE8F4E158D0Q33622976-EA7EC1E2-2A69-46BB-A205-F94CF01C7B5DQ33821520-F01779A0-9C72-4BFB-8792-0E7D46F67E4AQ34693386-1D5DFC63-BEE1-42A5-B088-C345B7CAD731Q35140751-BC48A29D-60EF-4122-9FB7-765D2E7EE3E7Q35278325-3C9C2166-D03A-4CDB-AE10-CD50CECA6162Q35746206-51D745A0-3AE6-497D-9D28-3B28D4B58E2AQ36741884-DB35D27F-CEC7-4EAA-ACDC-D4BDB137C6FCQ37057340-531A96B5-BD0F-46E7-94DD-F67CE7B29E26Q37263756-6CE12FF7-AA43-475D-BCD7-B12E80DD2888Q37287904-9C1D017D-FC72-4367-8B83-ECD5CDF666ECQ37411475-141C1B93-F9CE-4240-8F5F-E4B92D4D61D7Q37481946-4F75471F-C780-4F32-B231-7180BBE31E23Q38232197-F6CDB3A1-914C-4006-A1D9-2FAF45E2BE6FQ38233288-E417E4E5-8EBD-4068-B6FE-ADF0B2315DC6Q38233471-EDB32019-005D-4A31-8305-52B477CF3B63Q38536299-F8489E01-C611-4A18-8F39-31CDB8080FDEQ38544966-85FED40C-5979-4113-AC83-53A88629150BQ38646905-BEDFF520-98BA-4A49-8D58-5E8F1ED66762Q38672879-C43B120C-9505-4509-8065-41464AF363C7Q39038590-C317CE48-95D0-4CCB-A04C-496235148850Q39309271-70CD90CE-8DB5-446A-985A-04E55FD6EB5DQ40476599-F01AB76F-2230-4220-9DA2-0932D92C6DF1Q41987708-CC66DDD8-2CB7-4AEC-BFAD-F9DC1755DAB6Q42268705-CE1FFEDC-45C6-4603-A964-6EE98A50C0A2Q43202091-5BD60FD9-98C2-4888-BEE4-0C1EE92F0D87Q43563522-A77C93F8-0448-4E8A-8E01-D07F02693ED5Q45072823-3B0EC77C-8B21-4971-BF2C-19ECAA022102Q46181087-15163A85-C4C7-4BDB-A4F4-944C504D3211Q47573172-61BB9E91-049A-4EC3-B4FE-9F952A2E1AC3Q48100715-3B975166-2CD6-469D-A62A-EF0B4FF3617EQ54207272-57272541-EF7F-4224-8FDA-BBAB534305A1
P2860
White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
White paper: recommendations o ...... -resistant bacterial pathogens
@en
type
label
White paper: recommendations o ...... -resistant bacterial pathogens
@en
prefLabel
White paper: recommendations o ...... -resistant bacterial pathogens
@en
P2860
P356
P1476
White paper: recommendations o ...... -resistant bacterial pathogens
@en
P2860
P304
P356
10.1093/CID/CIS688
P407
P577
2012-08-13T00:00:00Z